Compare Transocean Ltd (RIG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Transocean Ltd trades at $5.55 (market cap $6.19B), while Vertex Pharmaceuticals Incorporated trades at $510.9 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 20.6× Transocean Ltd's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RIG | VRTX | |
|---|---|---|
Market Cap | $6.19B | $127.55B |
Volume | 30,564,415 | 1,487,944 |
Sector | Energy | Health |
52-Week High | $7.58 | $557.96 |
52-Week Low | $3.08 | $407.37 |
Typical Hold Time | 18 Days | 120 Days |
Enterprise Value | $10.80B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.595, up 3.8% with bullish technical signals despite mixed earnings. The company shows strong revenue growth to $4.1B in 2026 but remains unprofitable with a -40.24% net margin. Recent $80M and $300M contract wins boost backlog, while the $5.8B Valaris acquisition advances after DOJ approval. Cash flow improved with $995M operating cash in 2026, supporting deleveraging efforts amid high debt levels.
RIG offers speculative upside through offshore cycle leverage and contract growth, but high debt and persistent losses pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about cash flow improvement versus concerns over profitability and execution risks from major acquisitions.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
